Birgitta Versluijs

144 Results FIGURE 3. Cumulative incidence of Non Relapse Mortality (NRM) according to therapy response. Allo-LS, Alloimmune mediated lung syndrome 17 % ± 14 % 83 % ± 16 % p<0.001** 0.00 0.25 0.50 0.75 1.00 0 300 600 900 Time after Allo−LS onset NRM Incidence a a Responded to therapy Therapy failed 29 25 22 20 24 6 4 3 − − Number at risk Therapy failure according to ICU admission (55% vs 37%, p=0.015) and GvHD (100% vs 37%, p=0.002), as well as NRM according to RV presence (26% vs 72% p=0.02) and ICU admission (68% vs 33%, p=0.003) are shown in Figure S1 a,b and Figure S2 a,b. In the additional exploratory analyses in BOS patients we related baseline PFT with Allo- LS free survival. FEV1/FVC (HR0.94, 95% CI 0.90-0.99, p=0.02) was the only predictor found, higher values predicting good outcome. We also related early response (values of PFT after a median of 8 (5-53) days following first MP pulse) to Allo-LS free survival. Higher absolute FEV1% (HR 0.94 (0.89-0.98), p=0.01) and increase of FEV1% (HR 0.84, 95% CI 0.73-0.96, p= 0.01) on repeated PFT, were an indicator for better outcome. (see Table S4) 8 29 25 22 24 6 3 4 20 17% ± 14% 83% ± 16% p<0.001* * —  Responded to therapy —  Therapy failed Time after Allo-LS onset (days) 0 300 Number at risk 600 900 NRM incidence 1, 0,75 0,50 0,25